Diaceutics up 7% on strong revenue growth and positive outlook
- Revenue up 40% driven by rapid adoption of subs- Average revenue per brand £0.3m- potential for £3m- Two-year investment plan to drive enhanced growthDiagnostics commercialisation platform provider Diaceutics (DXRX:AIM) delivered a 40% increase in full year 2022 revenues to £19.5 million driven by a significant shift to platform-based subscription contracts which jumped nine-fold, representin